432 related articles for article (PubMed ID: 38418707)
41. Targeting co-stimulatory molecules in autoimmune disease.
Edner NM; Carlesso G; Rush JS; Walker LSK
Nat Rev Drug Discov; 2020 Dec; 19(12):860-883. PubMed ID: 32939077
[TBL] [Abstract][Full Text] [Related]
42. Thyroid Immune-Related Adverse Events in Patients with Cancer Treated with anti-PD1/anti-CTLA4 Immune Checkpoint Inhibitor Combination: Clinical Course and Outcomes.
Lui DTW; Lee CH; Tang V; Fong CHY; Lee ACH; Chiu JWY; Leung RCY; Kwok GGW; Li BCW; Cheung TT; Woo YC; Lam KSL; Yau T
Endocr Pract; 2021 Sep; 27(9):886-893. PubMed ID: 33581327
[TBL] [Abstract][Full Text] [Related]
43. Targeting CTLA-4 in cancer: Is it the ideal companion for PD-1 blockade immunotherapy combinations?
De Silva P; Aiello M; Gu-Trantien C; Migliori E; Willard-Gallo K; Solinas C
Int J Cancer; 2021 Jul; 149(1):31-41. PubMed ID: 33252786
[TBL] [Abstract][Full Text] [Related]
44. Immune checkpoint inhibitors and cancer immunotherapy by aptamers: an overview.
Kejamurthy P; Devi KTR
Med Oncol; 2023 Dec; 41(1):40. PubMed ID: 38158454
[TBL] [Abstract][Full Text] [Related]
45. Vasculitis associated with immune checkpoint inhibitors-a systematic review.
Daxini A; Cronin K; Sreih AG
Clin Rheumatol; 2018 Sep; 37(9):2579-2584. PubMed ID: 29923081
[TBL] [Abstract][Full Text] [Related]
46. Chimeric antigen receptor engineering: a right step in the evolution of adoptive cellular immunotherapy.
Figueroa JA; Reidy A; Mirandola L; Trotter K; Suvorava N; Figueroa A; Konala V; Aulakh A; Littlefield L; Grizzi F; Rahman RL; Jenkins MR; Musgrove B; Radhi S; D'Cunha N; D'Cunha LN; Hermonat PL; Cobos E; Chiriva-Internati M
Int Rev Immunol; 2015 Mar; 34(2):154-87. PubMed ID: 25901860
[TBL] [Abstract][Full Text] [Related]
47. Immune Checkpoint Inhibitors: New Insights and Current Place in Cancer Therapy.
La-Beck NM; Jean GW; Huynh C; Alzghari SK; Lowe DB
Pharmacotherapy; 2015 Oct; 35(10):963-76. PubMed ID: 26497482
[TBL] [Abstract][Full Text] [Related]
48. An overview of immune checkpoint therapy in autoimmune diseases.
Mohammadi P; Hesari M; Chalabi M; Salari F; Khademi F
Int Immunopharmacol; 2022 Jun; 107():108647. PubMed ID: 35228033
[TBL] [Abstract][Full Text] [Related]
49. Cancer immunotherapy with check point inhibitor can cause autoimmune adverse events due to loss of Treg homeostasis.
Kumar P; Saini S; Prabhakar BS
Semin Cancer Biol; 2020 Aug; 64():29-35. PubMed ID: 30716481
[TBL] [Abstract][Full Text] [Related]
50. Immune checkpoint inhibitors for cancer treatment.
Park J; Kwon M; Shin EC
Arch Pharm Res; 2016 Nov; 39(11):1577-1587. PubMed ID: 27770382
[TBL] [Abstract][Full Text] [Related]
51. What did we learn from CTLA-4 insufficiency on the human immune system?
Mitsuiki N; Schwab C; Grimbacher B
Immunol Rev; 2019 Jan; 287(1):33-49. PubMed ID: 30565239
[TBL] [Abstract][Full Text] [Related]
52. A Threshold Model for T-Cell Activation in the Era of Checkpoint Blockade Immunotherapy.
Guram K; Kim SS; Wu V; Sanders PD; Patel S; Schoenberger SP; Cohen EEW; Chen SY; Sharabi AB
Front Immunol; 2019; 10():491. PubMed ID: 30936880
[TBL] [Abstract][Full Text] [Related]
53. Tumor immune checkpoints and their associated inhibitors.
Gao Z; Ling X; Shi C; Wang Y; Lin A
J Zhejiang Univ Sci B; 2022 Oct; 23(10):823-843. PubMed ID: 36226537
[TBL] [Abstract][Full Text] [Related]
54. Role of Next Generation Immune Checkpoint Inhibitor (ICI) Therapy in Philadelphia Negative Classic Myeloproliferative Neoplasm (MPN): Review of the Literature.
Yadav R; Hakobyan N; Wang JC
Int J Mol Sci; 2023 Aug; 24(15):. PubMed ID: 37569880
[TBL] [Abstract][Full Text] [Related]
55. [IMMUNOTHERAPY WITH CHECKPOINT INHIBITORS (ICPI) AND IMMUNE RELATED ADVERSE EVENTS (IRAE'S)].
Ben Zvi C; Ehrenfeld M; Shoenfeld Y
Harefuah; 2020 Jul; 159(7):508-515. PubMed ID: 32720769
[TBL] [Abstract][Full Text] [Related]
56. Immune checkpoint therapy for non-small-cell lung cancer: an update.
Xia B; Herbst RS
Immunotherapy; 2016; 8(3):279-98. PubMed ID: 26860624
[TBL] [Abstract][Full Text] [Related]
57. Regulation of PD-L1 Expression by NF-κB in Cancer.
Antonangeli F; Natalini A; Garassino MC; Sica A; Santoni A; Di Rosa F
Front Immunol; 2020; 11():584626. PubMed ID: 33324403
[TBL] [Abstract][Full Text] [Related]
58. Haematological immune-related adverse events with immune checkpoint inhibitors, how to manage?
Michot JM; Lazarovici J; Tieu A; Champiat S; Voisin AL; Ebbo M; Godeau B; Michel M; Ribrag V; Lambotte O
Eur J Cancer; 2019 Nov; 122():72-90. PubMed ID: 31634647
[TBL] [Abstract][Full Text] [Related]
59. Immuno-regulatory antibodies for the treatment of cancer.
Honeychurch J; Cheadle EJ; Dovedi SJ; Illidge TM
Expert Opin Biol Ther; 2015 Jun; 15(6):787-801. PubMed ID: 25882106
[TBL] [Abstract][Full Text] [Related]
60. Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors.
De Martin E; Michot JM; Papouin B; Champiat S; Mateus C; Lambotte O; Roche B; Antonini TM; Coilly A; Laghouati S; Robert C; Marabelle A; Guettier C; Samuel D
J Hepatol; 2018 Jun; 68(6):1181-1190. PubMed ID: 29427729
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]